ArticleFrontiers in cardiovascular medicine2026
Pretreatment cardiometabolic risk in newly diagnosed breast cancer: a molecular subtype analysis.
Article in Frontiers in cardiovascular medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Breast cancer is the most common female malignancy globally. With improved survival, cardiovascular diseases have become a key morbidity source due to shared cardiometabolic risk factors (e.g., dyslipidemia). While cardiovascular risk varies by breast cancer molecular subtype, baseline pre-treatment cardiovascular comorbidities and lipid abnormalities remain undercharacterized. We aimed to describe their prevalence and subtype-specific patterns in newly diagnosed patients. Methods: This single-center retrospective cohort study included 5,246 Chinese women with newly diagnosed breast cancer (2014-2024), with all data collected before anticancer therapy. Patients were stratified into five molecular subtypes. Baseline cardiovascular comorbidities, tumor features, and serum lipids were analyzed using chi-square tests, ANOVA, and multivariable logistic regression. Results: Age, cardiovascular comorbidities, electrocardiographic abnormalities and lipid profiles differed significantly across subtypes. Overall dyslipidemia prevalence was 54.1%, highest in Luminal A and lowest in Luminal B (HER2 negative). Intravascular tumor thrombus was independently associated with dyslipidemia in all subtypes, with the strongest association in triple-negative breast cancer. Lymph node metastasis correlated with dyslipidemia only in Luminal B subtypes, and several factors showed subtype-specific associations. Conclusions: Dyslipidemia is common at baseline in treatment-naive breast cancer patients and varies by molecular subtype. Tumor-related features, particularly intravascular tumor thrombus, are consistently associated with dyslipidemia. Early lipid screening and cardiovascular risk assessment may optimize cardio-oncology care.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.